No­var­tis ex­ecs high­light progress of slim­mer pipeline af­ter San­doz spin­off

No­var­tis ex­ec­u­tives on Tues­day crys­tal­lized their on­go­ing R&D strat­e­gy shift in the wake of the San­doz spin­off, with CEO Vas Narasimhan and oth­ers out­lin­ing how the com­pa­ny aims to be more ef­fi­cient and its de­ci­sions stream­lined.

Gone are the days of “Wild Card” drugs, re­placed by a slimmed-down pipeline with much more “align­ment” across de­part­ments about which dis­eases to tack­le. It marks a shift from the past, the CEO said, about mak­ing sure No­var­tis is “very, very clear” on the dis­eases it wants to treat and drugs it wants to pur­sue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER